Abstract:Aiming to explore novel BRAFV600E and VEGFR-2 dual inhibitors, a series of 1H-pyrazolo[3,4-d]pyrimidine derivatives were designed, synthesized and biologically evaluated in this study. Most of the synthesized 1H-pyrazolo[3,4-d]pyrimidine compounds displayed moderate to high potent activity in both enzymatic and cellular proliferation assays. Among these compounds, 9e, 9g, 9m and 9u showed remarkably high inhibitory activities against both BRAFV600E and VEGFR-2 kinase comparable to positive control Sorafenib. Particularly, compound 9u also showed potent anti-proliferative activity against BRAFV600E-expressing A375 (IC50 = 1.74 μM) and H-29 (IC50 = 6.92 μM) as well as VEGFR-2-expressing HUVEC (IC50 = 5.89 μM), which was also comparable to Sorafenib. Furthermore, kinase selectivity profile showed that 9u had almost poor or no significant inhibitory activity against wild-type BRAF and 15 other tested protein kinases. Flow cytometric analysis showed that compound 9u mainly arrested the A375 and HUVEC cell lines in the G0/G1 stage with a concentration-dependent effect. In addition, the molecular docking and molecular dynamics simulations suggested that 9u adopted a similar binding pattern with Sorafenib at the ATP-binding sites of BRAFV600E and VEGFR-2. Taken together, these results indicated that compound 9u may serve as novel lead compound in research on more effective BRAFV600E and VEGFR-2 dual inhibitors.

Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Synthesis, Crystal Structures, Fluorescence and Xanthine Oxidase Inhibitory Activity of Pyrazole-Based 1,3,4-Oxadiazole Derivatives

Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives As Dipeptidyl Peptidase 4 Inhibitors.

Synthesis and bioactivity of pyrazole and triazole derivatives as potential PDE4 inhibitors.

Discovery and optimization of 4-(imidazo[1,2-a]pyrimidin-3-yl)thiazol-2-amine derivatives as novel phosphodiesterase 4 inhibitors

Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

Design, Synthesis and Biological Evaluation of Novel Tetrahydroisoquinoline Derivatives As Potential PDE4 Inhibitors.

Design, synthesis, and biological evaluation of some new 2-phenyl-3,6-pyridazinedione derivatives as PDE-5 inhibitors

Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors

Design, synthesis, biological evaluation and molecular dynamics simulation studies of imidazolidine-2,4-dione derivatives as novel PTP1B inhibitors

Design, synthesis and biological evaluation of 2,4-disubstituted oxazole derivatives as potential PDE4 inhibitors

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Synthesis and Bioactivity of 3,5-Dimethylpyrazole Derivatives As Potential PDE4 Inhibitors.

Design, Synthesis, and Evaluation of Dihydropyranopyrazole Derivatives as Novel PDE2 Inhibitors for the Treatment of Alzheimer’s Disease

Design of Novel Thiazole Bearing Pyrazole Derivatives and Their Dual Activities as ACE Inhibitors and Calcium Channel Blockers in Cardiovascular Disease

Design, Synthesis, Biological Evaluation and Molecular Modeling of Novel 1H-Pyrazolo[3,4-d]pyrimidine Derivatives As BRAF(V600E) and VEGFR-2 Dual Inhibitors

Synthesis of 2,4-dihydroxyacetophenone derivatives as potent PDE-1 and -3 inhibitors: in vitro and in silico insights

Synthesis, Biological Evaluation and Molecular Docking Studies of Pyrazole Derivatives Coupling with a Thiourea Moiety As Novel CDKs Inhibitors.

Design, Synthesis, and Biological Evaluation of Pyrido[2,3- d ]pyrimidin-7(8 H )-one Derivatives As Potent USP1 Inhibitors